We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
News

Senescent Cell Research Moves into Human Trials

Rectangle Image
News

Senescent Cell Research Moves into Human Trials

Image credit: Pixabay
Read time:
 

Findings from a safety and feasibility clinical trial on the removal of senescent cells from a small group of patients with pulmonary fibrosis have been published in EBioMedicine.

While lung function, clinical test outcomes, frailty levels and overall health among the patients did not change, all 14 participants showed clinically meaningful improvement in physical function in nine doses over three weeks. That ability was measured in four tests: gait speed, walking speed in six minutes, a chair rise test and a score related to a bank of physical function tests.

“This was a short safety trial to determine if we should move ahead with actual large-scale human trials,” says senior author James Kirkland, M.D., Ph.D., head of the Robert and Arlene Kogod Center on Aging. “It's important to emphasize that, while some measurable improvement was noted in all the participants, this is simply the start of human studies. We don't know what lies ahead.”

Read more from the University of Texas San Antonio press release here.

Senescent or semidormant cells (sometimes called "zombie cells") form in many areas of the body and cause aspects of aging and frailty, ranging from osteoporosis to diabetes and muscle weakness. In this case, researchers are focusing on idiopathic pulmonary fibrosis, a progressive and fatal condition that is related to senescent cells. The researchers used a drug called a senolytic – dasatinib plus quercetin, an open-label drug, to clear the senescent cells.

“We are studying the effectiveness of this and other senolytic drugs, but that does not mean that these should be used by patients or prescribed by physicians for any off-label conditions,” says Dr. Kirkland. “I want to emphasize that no one should take these drugs. This research is only beginning.”

This article has been republished from materials provided by the Mayo Clinic. Note: material may have been edited for length and content. For further information, please contact the cited source.

Reference:

Justice, J. N., Nambiar, A. M., Tchkonia, T., Lebrasseur, N. K., Pascual, R., Hashmi, S. K., . . . Kirkland, J. L. (2019). Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine. doi:10.1016/j.ebiom.2018.12.052

Advertisement